Stay updated on Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page
- Check3 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the former content with an error page. This change blocks access to the study details, contacts, locations, and related documents that users expect to see on the page.SummaryDifference19%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.6.6 was added, replacing the prior Revision: v3.6.5. This reflects a minor update to the page's versioning metadata.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a small version update to the page.SummaryDifference0.1%

- Check59 days agoChange DetectedThe revision label on the page was updated from Revision: v3.6.3 to Revision: v3.6.4, indicating a new build of the page.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page revision changed from v3.6.2 to v3.6.3, indicating a minor platform update. No study content or visible details were altered.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page now displays Revision: v3.6.2 instead of v3.6.0. This indicates an updated release of study documents or page content.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.